Acute intermittent porphyria (AIP) is an inherited disorder of haem production associated with pathogenic variants in HMBS. The practical diagnostic distinction is between having a genetic predisposition and having symptoms caused by an acute attack. A DNA result addresses the first question. Appropriately collected biochemical tests, interpreted with the clinical presentation, are central to the second.

Severe unexplained abdominal pain accompanied by new weakness, confusion, seizures or breathing difficulty needs urgent medical assessment. Do not wait for a genetic test or an online interpretation before seeking care.

Which test is useful during suspected symptoms?

The AGA clinical practice update recommends a random urine sample measuring porphobilinogen (PBG), delta-aminolevulinic acid (ALA) and creatinine as initial testing for a suspected acute hepatic porphyria. Creatinine helps account for urine dilution. A 24-hour collection is not required for this initial assessment. An order for “urine porphyrins” alone is not an equivalent test: mildly increased porphyrins can have other explanations. AGA clinical practice update, 2023.

Testing is most informative during symptoms, preferably before specific treatment when feasible without delaying care. Follow the receiving laboratory’s instructions for light protection, storage and transport. If a sample is very dilute, taken after treatment or handled incorrectly, the circumstances must be considered before interpreting a reassuring result. American Porphyria Foundation: diagnosis and testing.

Simplified educational pathway: urgent symptoms need assessment; urine PBG, ALA and creatinine are interpreted with symptoms, timing and handling. An abnormal result leads to specialist confirmation; a non-supportive result requires checking context and other causes.
Simplified educational pathway: urgent symptoms need assessment; urine PBG, ALA and creatinine are interpreted with symptoms, timing and handling. An abnormal result leads to specialist confirmation; a non-supportive result requires checking context and other causes.

Open full-size illustration (new tab)

Why serum, plasma, whole blood and PBMCs are not interchangeable

Material or testWhat question it may addressImportant limit
Urine PBG, ALA and creatinineBiochemical evidence relevant to a suspected acute hepatic porphyriaTiming, dilution and treatment affect interpretation
Blood for DNA analysisAn inherited variant, including HMBSDoes not show that today’s pain is an attack
Plasma or faecal porphyrin studiesSpecialist differentiation of porphyria typesNot a generic substitute for initial urine precursor testing
PBMC measurementsResearch questions involving peripheral blood mononuclear cellsA research assay is not an established routine first-line attack test

These tests are chosen for different purposes. In particular, a paper measuring something in PBMCs does not establish that the same measurement is suitable for diagnosing a person with abdominal pain. The laboratory method, validation and intended clinical use matter. Acute porphyrias and their distinguishing laboratory findings.

What does a raised PBG result establish?

A substantial rise supports an acute hepatic porphyria in the right setting, but additional work is needed to determine its type and interpret current symptoms. PBG can remain elevated between attacks in AIP. An isolated raised result therefore cannot time an attack by itself. Specialists consider symptoms, other explanations, previous results and the biochemical pattern. GeneReviews uses clinical history and biochemical activity to distinguish latent, asymptomatic and symptomatic categories; these are not inevitable sequential “stages” through which every person progresses. GeneReviews: acute intermittent porphyria.

Three examples that prevent common mistakes

Fictional example: the wrong test was ordered. A patient with recurrent pain brings a report showing a small increase in total urine porphyrins. It does not list PBG, ALA or creatinine. Rather than calling this AIP, the clinician checks exactly what was measured and arranges the appropriate biochemical assessment while evaluating other causes.

Fictional example: a familial HMBS result. A well adult tests positive for a pathogenic variant previously established in a relative. This identifies susceptibility and supports prevention advice and family counselling. It does not establish that every future headache or stomach ache is porphyria. The clinician agrees an assessment plan for significant symptoms.

Fictional example: a result after treatment. An emergency sample is collected only after porphyria-directed treatment has started. The team documents the timing and asks the specialist laboratory how that affects interpretation. A negative result without this context would answer a different question from an untreated sample taken during symptoms.

How does inheritance fit in?

AIP is usually associated with one pathogenic HMBS variant and follows autosomal dominant inheritance with low penetrance. Each child of a heterozygous parent has a 50% chance of inheriting the variant, but that is not a 50% prediction of symptomatic attacks. A variant of uncertain significance should not be treated as a confirmed familial diagnosis. GeneReviews inheritance guidance.

Bring these details to a specialist discussion

  • The exact symptoms, timing and treatments given before sampling.
  • The named analytes, specimen type, units, reference intervals and creatinine-adjusted results.
  • Previous biochemical results, including symptom-free measurements if available.
  • The complete genetic report and any established familial variant.
  • A medication list for an appropriate porphyria-safety review; do not stop prescribed treatment on your own.

Our guides to penetrance and uncertain variants explain the distinction between susceptibility and diagnosis. The variant evidence worksheet can organize a report, and the care directory can help locate professional services.